Cell Cryopreservation Market

The global Cell Cryopreservation Market is valued at USD 13.15 Billion in 2023 and is projected to reach a value of USD 60.25 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 18.4% between 2024 and 2032.

Key highlights of Cell Cryopreservation Market

• The North American region has shown its dominance in the market in 2023, obtaining the largest revenue share of more than 45.7%,
• In 2023, the Europe region is expected to have a substantial market share and be experiencing remarkable growth,
• The Consumables segment dominates the market with 43.8% of the market share in 2023,
• The Stem Cells segment will continue to assert its dominance by position, capturing the largest market share of 36.2% in 2023,
• IVF Clinics dominated the market with a significant market share of 43.1% in 2023,
• Additionally, favorable government initiatives, investments in healthcare infrastructure, and collaborations between research institutions and industry players drive innovation and market expansion in the cell cryopreservation sector.

Cell Cryopreservation Market: Regional Overview

North America Dominated Sales with a 45.7% share in 2023. North America's leadership in the Cell Cryopreservation market is sustained by a conducive regulatory environment fostering research and development, and a high level of healthcare expenditure, and strong government support for biotechnology advancements. Moreover, the region benefits from a well-established network of academic and research institutions collaborating closely with industry players, driving innovation and technology transfer. As the area continues to prioritize advancements in healthcare and biotechnology, North America is poised to maintain its leading position in the Cell Cryopreservation market, driving continued growth and innovation in the years to come.

U.S. Cell Cryopreservation Market Overview

The U.S. Cell Cryopreservation market, valued at USD 4.02 Billion in 2023 to USD 17.54 Billion in 2032, is anticipated to grow at a CAGR of 17.8% from 2024 to 2032. The market for Cell Cryopreservation in the USA is constantly growing and evolving because of a strong emphasis on biomedical research. The United States is a key player in advancing cell-based therapies, regenerative medicine, and drug discovery, driving significant demand for cryopreservation solutions. Major factors contributing to the market's growth include increasing investment in biotechnology research, supportive regulatory frameworks, and a well-established healthcare infrastructure. Additionally, leading companies specializing in cryopreservation technologies and strategic collaborations between academia, industry, and government institutions further propel market expansion.

The global Cell Cryopreservation market can be categorized as Product, Application, End Use, and Region.

Cell Cryopreservation Market: Product Overview

In 2023, the Consumables segment dominated the market with 43.8% market share. The {Keyword}} market, segmented by product, includes Cell Freezing Media, Equipment, and Consumables. This dominance can be attributed to the essential role of consumable products such as Cryogenic Vials, Cryogenic Tubes, Cooler, Boxes/Containers, and related consumables among end-users, driven by advantages such as reduced contamination risks. Additionally, factors, which include the increasing occurrence of chronic sicknesses, heightened demand for biologics, and developing interest in cryopreservation amongst the End Users, are anticipated to propel the section's expansion. As cryopreservation strategies hold to build, there's an increasing call for high-quality consumables that provide more suitable performance, reproducibility, and safety. Key factors contributing to the segment's growth include the rising adoption of cell-based therapies, expanding biobanking activities, and ongoing research and development initiatives aimed at improving cryopreservation protocols.

Cell Cryopreservation Market: Application Overview

In 2023, the Stem Cells segment accounted for over 36.2% market share. The Application segment is divided into Stem Cells, Oocytes and Embryotic cells, Sperm Cells, Hepatocytes, and Other Applications. This dominance underscores the pivotal function of cryopreservation techniques in maintaining the viability and capability of stem cells, which preserve substantial promise in regenerative remedies, research, and therapeutic applications. The segment's boom is fueled by increasing investments in stem cell research, expanding applications in regions consisting of tissue engineering and cell-based therapies, and growing awareness about the potential of stem cells to cope with diverse medical conditions. The burden of cardiovascular disease will increase due to the aging population and sedentary lifestyles, which will drive the segment's growth. For instance, Cardiovascular illnesses continue to affect over half a billion people worldwide, accounting for 20.5 million deaths in 20231 – about a third of the total mortality worldwide and an overall rise above the anticipated 121 million CVD deaths. Moreover, advancements in cryopreservation technologies tailored to meet the specific requirements of stem cells further contribute to the segment's expansion, driving continued innovation and adoption in the market.

Cell Cryopreservation Market: End Use Overview

The IVF Clinics segment accounted for the largest market share of 43.1% in 2023. The End Use segment is bifurcated into Biopharmaceutical & Pharmaceutical Companies, Research Institutes, Biobanks, IVF Clinics, and Other End Uses. This huge presence underscores the important role of cryopreservation strategies in assisted reproductive technology, particularly in in-vitro fertilization (IVF) clinics, in which cryopreservation is considerably utilized to keep gametes (eggs and sperm) and embryos. The segment's growth is driven by increasing infertility rates, rising demand for fertility treatments, and advancements in cryopreservation protocols enhancing the success rates of IVF procedures. Additionally, the growing trend towards delayed parenthood and the increasing acceptance of alternative family-building options further contribute to the segment's expansion. As IVF clinics continue to adopt and refine cryopreservation technologies to improve patient outcomes and address infertility challenges, the segment is poised for continued growth and innovation in the cell cryopreservation market.

Key Trends

• The need for cell-based therapies and customized medicine grows, and effective cryopreservation methods are required to maintain cellular integrity during storage and transport.
• Developments in cryoprotectant solutions and freezing methods are improving the viability and recovery costs of cryopreserved cells, establishing new avenues for use in fields such as stem cell research and the production of cell therapies.
• The development of automated and closed-system cryopreservation platforms is making cell banking and bioprocessing more efficient and scalable by optimizing the procedure, lowering the risk of contamination, and enhancing reproducibility.
• With increasing regulatory scrutiny and standardization, businesses are being compelled to invest in quality control procedures and adhere to strict rules to guarantee the security and effectiveness of cryopreserved cellular products.

Premium Insights

The increasing prevalence of chronic diseases and the rising demand for personalized medicine drive the need for efficient storage and preservation of cells for therapeutic applications. For instance, six out of ten adults in the US have a chronic illness, and four out of ten persons have two or more, according to NCCDPHP (National Center for Chronic Disease Prevention and Health Prevention). Additionally, the growing uses of cell-based treatments in fields like neurology, cardiology, and oncology drive market expansion. The need for cryopreservation solutions is also fueled by the rise of biobanking programs and the expanding use of in vitro fertilization (IVF) methods. Increased collaboration, partnership, and expansion investments in the R&D sector have propelled market growth. For instance, the manufacturer of goods and services based on human cells, genes, and tissues, LifeCell International, unveiled Cellutions BioStorage, a research-to-launch cryopreservation bank. The new firm aims to close the growing gap in biospecimen preservation and maintenance caused by the supply chain by utilizing contemporary technologies.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

The growing prevalence of chronic diseases and the rising demand for cell-based therapies drives the Cell Cryopreservation market as cryopreservation enables the long-term storage and transportation of cells for therapeutic applications

The growing prevalence of chronic diseases, including cancer, diabetes, and cardiovascular disorders, presents a significant global health challenge, driving the need for innovative therapeutic approaches. The successful implementation of cell therapies hinges on the availability of viable cells, which often require precise storage conditions to maintain their integrity and functionality. Cryopreservation addresses this critical need by enabling the long-term preservation of cells at ultra-low temperatures, ensuring their viability and potency until they are ready for use in therapeutic applications. This capability extends the shelf life of cell-based products and facilitates their distribution and administration, thereby expanding access to these advanced treatments for patients worldwide.

High cost associated with cryopreservation technologies and services, which can limit adoption, particularly in resource-constrained settings

Cryopreservation involves sophisticated equipment, specialized cryogenic storage facilities, and expensive cryoprotectant solutions, all of which contribute to the overall cost of the process. These expenses can pose a substantial barrier to adoption for healthcare facilities or research institutions operating within limited budgets. Additionally, cryopreservation equipment's ongoing maintenance and operation costs further add to the financial burden. As a result, organizations in resource-constrained settings may struggle to afford the initial investment required to establish cryopreservation capabilities or may face challenges sustaining these operations over time. Consequently, get entry to cutting-edge cell-primarily based remedies and the wider adoption of cryopreservation strategies can be hampered with the aid of the high cost of cryopreservation technology and services. Addressing these cost-related challenges through innovative pricing models, technology optimization, and strategic collaborations is essential to broaden access to cryopreservation solutions and realize the full potential of cell-based therapies across diverse healthcare settings.

Technological advancements in cryoprotectant formulations, freezing methods, and storage solutions offer opportunities to enhance cell viability, improve preservation outcomes, and reduce costs

Cryoprotectants are crucial components in preserving cell viability during freezing and thawing processes, and ongoing research and development efforts are continually refining these formulations to improve efficacy and safety while minimizing cytotoxic effects. Similarly, innovations in freezing methods, such as vitrification techniques or controlled-rate freezing protocols, offer more precise control over the freezing process, resulting in higher post-thaw cell viability and functionality. Additionally, advancements in storage solutions, including cryogenic storage vessels and automated storage systems, enhance the long-term preservation of cryopreserved cells while optimizing space and minimizing operational costs. By leveraging these technological advancements, companies can strengthen preservation outcomes, increase the efficiency of cryopreservation processes, and ultimately reduce overall costs associated with cell storage and distribution.

Competitive Landscape

The Cell Cryopreservation market is highly competitive, driven by the increasing demand for reliable long-term storage solutions in biomedical research, regenerative medicine, and drug development. Key players such as Thermo Fisher Scientific, Merck KGaA, and GE Healthcare dominate the market with their extensive product portfolios, advanced technologies, and global distribution networks. Additionally, emerging players like BioLife Solutions and HiMedia Laboratories are gaining traction by focusing on innovation, strategic partnerships, and expansion into niche segments such as cell therapy and biobanking. With ongoing advancements in cryopreservation techniques and growing investments in R&D, the competitive landscape is expected to evolve rapidly, fostering collaboration and rivalry among industry participants striving to capture a larger market share.

The key players in the global Cell Cryopreservation market include - Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), PromoCell GmbH (Germany), Lonza (Switzerland), HiMedia Laboratories (India), Creative Biolabs (U.S.), Corning Inc. (U.S.), BioLife Solutions Inc. (U.S.) among others.

Recent Market Developments

• In 2023, BioLife Solutions, Inc. introduced a new controlled-rate freezer (CRF) with a large capacity, the IntelliRate i67C, to the larger biopharmaceutical markets. This tabletop freezer expands the CRF product line to accommodate different shape factors in the biopharmaceutical industry, meeting the key client demand for higher-volume manufacturing of cell therapies.
• AMSBIO has introduced 'STEM-CELLBANKER EX,' an advanced cryopreservation solution designed to accelerate the development of cell therapy products. This chemically defined cryopreservation medium solution offers a superior method for maintaining stem cells and advances the study and development of cell therapy. It contains inert components that are approved for intravenous delivery.